Bismab-A (lintuzumab-Bi-213)
/ Actinium Pharmaceuticals
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 27, 2015
Actinium: Future Leaders in the Biotech Industry
(Actinium Pharmaceuticals)
- Discontinuation of development due to supply, logistics, and cost reasons
Discontinued • Oncology
August 14, 2014
Actinium: Canaccord Genuity Growth Conference
(Actinium Pharmaceuticals)
- "Bismab-A Phase I/II Results"; "Median survival was 4x greater compared to historical data for untreated patients*"; "*Median survival was 7.6 months versus 1.7 months historically for untreated patients"
P1/2 data • Oncology
1 to 2
Of
2
Go to page
1